These results clearly demonstratethe great potential of our design strategy for G13-CRD-based antivirals.The lower potency of Sotrovimab against the authentic BA.1 over B.1variant is assigned to immune evasion mutations of S proteins in BA.1,which weakened Sotrovimab’s binding affinity and hence neutralizingpotency.14 This result is fully consistentwith the significantly reduced potencies observed for most neutralizingAbs and sera from past infections and/or vaccinations against theOmicron variant over the early pandemic B.1 variant.12,14,53. The gene discussed is PROS1; the disease is infection.